GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (LTS:0WA2) » Definitions » Price-to-Owner-Earnings

Cellectis (LTS:0WA2) Price-to-Owner-Earnings : (As of May. 22, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Cellectis Price-to-Owner-Earnings?

As of today (2024-05-22), Cellectis's share price is €2.67. Cellectis does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Cellectis's Price-to-Owner-Earnings or its related term are showing as below:


LTS:0WA2's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.52
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-22), Cellectis's share price is €2.67. Cellectis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €-1.65. Therefore, Cellectis's PE Ratio for today is At Loss.

As of today (2024-05-22), Cellectis's share price is €2.67. Cellectis's EPS without NRI for the trailing twelve months (TTM) ended in was €-1.78. Therefore, Cellectis's PE Ratio without NRI for today is At Loss.

During the past 13 years, Cellectis's highest PE Ratio without NRI was 129.84. The lowest was 0.00. And the median was 96.19.


Cellectis Price-to-Owner-Earnings Historical Data

The historical data trend for Cellectis's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectis Price-to-Owner-Earnings Chart

Cellectis Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cellectis Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cellectis's Price-to-Owner-Earnings

For the Biotechnology subindustry, Cellectis's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cellectis's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Cellectis's Price-to-Owner-Earnings falls into.



Cellectis Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Cellectis's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=2.67/-0.67
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cellectis  (LTS:0WA2) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Cellectis Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Cellectis's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectis (LTS:0WA2) Business Description

Traded in Other Exchanges
Address
8, rue de la Croix Jarry, Paris, FRA, 75013
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reports two segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.

Cellectis (LTS:0WA2) Headlines

No Headlines